A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

717

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
COPD
Interventions
DRUG

Arformoterol tartrate inhalation solution

Arformoterol 50 mcg QD

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 25 mcg BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 15 mcg BID

DRUG

Salmeterol MDI

Salmeterol MDI 42 mcg BID

DRUG

Placebo

Placebo BID MDI

Trial Locations (52)

Unknown

Anniston

Birmingham

Jasper

Mobile

Oxford

Little Rock

Los Angeles

Mirage

Mission Hills

San Diego

Santa Ana

Signal Hill

Colorado Springs

Denver

Wheat Ridge

Clearwater

DeLand

Miami

Ocala

Pensacola

St. Petersburg

Tampa

Atlanta

Austell

Decatur

Bloomington

Evansville

Shawnee Mission

Minneapolis

Charles

Las Vegas

Margate City

South Bound Brook

Albuquerque

Endwell

Ithaca

New York

Charlotte

Raleigh

Spartanburg

Wilmington

Cincinnati

Tulsa

Medford

Pittsburgh

Charleston

Houston

Irving

San Antonio

Chesapeake

Richmond

Tacoma

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00685841 - A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter